<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867330</url>
  </required_header>
  <id_info>
    <org_study_id>2020-OR001</org_study_id>
    <nct_id>NCT04867330</nct_id>
  </id_info>
  <brief_title>Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC</brief_title>
  <official_title>Induction Chemotherapy of Toripalimab With Docetaxel and Cisplatin Followed by De-escalation of Chemoradiotherapy Density in HPV-related Oropharyngeal Carcinoma in Chinese Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive.&#xD;
      Several studies attempted to reduce the toxicities of treatments through reduced-dose&#xD;
      radiation and showed promising results, but all data were collected from non-Chinese areas.&#xD;
      Like nasopharyngeal carcinoma (NPC), oropharyngeal carcinoma may have different biological&#xD;
      behavior and relationship with HPV infection. So the investigators studied whether toxicities&#xD;
      reducing treatment with reduced radiation dose and omitted concurrent chemotherapy after good&#xD;
      response to induction chemotherapy would maintain survival outcomes while improving&#xD;
      tolerability for patients with HPV-positive oropharyngeal carcinoma. Immune checkpoint&#xD;
      inhibitors (ICIs) have proved to improve outcomes of head and neck cancers including&#xD;
      EBV-related NPC. Oropharyngeal carcinoma was considered to be similar with NPC in terms of&#xD;
      immune environment. So we added anti-PD-1 antibody Toripalimab to induction chemotherapy in&#xD;
      order to achieve better response rates to receive de-escalation chemoradiotherapy followed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS PFS</measure>
    <time_frame>2 year</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Oropharyngeal Carcinoma</condition>
  <condition>Immune Checkpoint Inhibitor</condition>
  <condition>De-escalation</condition>
  <arm_group>
    <arm_group_label>conventional treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Toxicities reduced treatment arm</intervention_name>
    <description>Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)</description>
    <arm_group_label>conventional treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of squamous cell carcinoma of oropharynx with IHC p16&#xD;
&#xD;
          -  positive or PCR HPV16 positive&#xD;
&#xD;
          -  T1-2/N1-3M0（except T1N1M0 and single LN&lt;3cm）or T3-4N0-3M0 according to UICC/AJCC 8th&#xD;
             staging system&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  No prior anti-tumor treatment&#xD;
&#xD;
          -  Karnofsky Performance Score (KPS)≥70&#xD;
&#xD;
          -  Adequate blood supply&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cannot take contrast-MRI imaging&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Combined with other malignant tumor (except basal cell carcinoma of skin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chaosu Hu, MD</last_name>
    <phone>+8618017312903</phone>
    <email>hucsu62@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan Universtiy Shanghai Cancer Centre</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tingting xu, MD</last_name>
      <phone>+8618017312903</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chaosu Hu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

